Pregabalin Capsule
Product Images NDC 71335-9740

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71335-9740). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713359740)

Label for Pregabalin Capsules, USP 300 mg by Bryant Ranch Prepack. The label indicates 60 capsules in the package, repackaged by Bryant Ranch Prepack, Inc. and manufactured by ScieGen Pharmaceuticals, Inc. Storage instructions and a barcode are also included.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line chart showing the percent of patients improved versus percent improvement in pain from baseline. The chart compares four treatment groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo. Each treatment group is represented by a different line style.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline. Two lines represent treatment groups: Pregabalin 100 mg three times a day and placebo. The graph shows a higher percentage of patients with pain improvement on Pregabalin compared to placebo across the improvement range.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 300 mg twice daily, 150 mg twice daily, 75 mg twice daily, and placebo. Each line represents the improvement trend for the different dosing levels and placebo.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph comparing the percent of patients improved with Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The x-axis represents percent improvement in pain from baseline (0 to 100), and the y-axis shows the percent of patients improved (0 to 100). The graph visually demonstrates differences in pain improvement among the three groups over the range of improvement percentages.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line chart showing the percentage of patients improved on the vertical axis versus percent improvement in pain from baseline on the horizontal axis. It compares Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, illustrating the proportion of patients achieving various levels of pain improvement.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar graph comparing responder rates (%) between placebo and various dosages of the drug in two separate studies labeled E1 and E3. The x-axis shows treatment groups including placebo and different dosages, while the y-axis shows responder rates from 0% to 60%. Notes indicate statistical significance versus placebo.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph depicting seizure reduction as median percentage change from baseline versus dose in mg/day. Four study groups (Study E1 BD, Study E2 TID, Study E3 BD, Study E3 TID) are shown with markers representing different dosing schedules, with statistical significance (p-values) indicated for various doses. The graph emphasizes a dose-dependent seizure reduction effect relative to placebo.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Pregabalin 800mg daily dose, Pregabalin 450mg daily dose, Pregabalin 300mg daily dose, and placebo, with the Pregabalin 800mg group showing the highest improvement trends.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A line graph comparing the estimated percentage of subjects without LTR over 180 days between Pregabalin and placebo groups. The y-axis represents the estimated percentage without LTR from 0% to 100%, and the x-axis shows days from 0 to 180. The Pregabalin group shows a higher percentage of subjects without LTR over time compared to the placebo group.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved over various thresholds of percent improvement from baseline to week 12 in a BOCF analysis. It shows two lines: a solid line representing Pregabalin and a dotted line representing placebo, with the percent improved on the vertical axis and percent improved thresholds on the horizontal axis.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line chart comparing the percent of subjects improved by various percentages from baseline to week 16 according to the Baseline Observation Carried Forward (BOCF) method. The chart shows two lines: one solid line representing Pregabalin and one dotted line representing placebo, with the Pregabalin line consistently higher across improvement percentages.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A formula calculation panel showing how to calculate creatinine clearance (CLcr) by using age, weight, and serum creatinine, with an adjustment factor of 0.85 for female patients. This is a dosing-related equation often included in prescribing information.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of pregabalin, showing its molecular configuration with labeled functional groups including amino and carboxyl groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.